Form 8-K - Current report:
SEC Accession No. 0001520138-21-000249
Filing Date
2021-05-10
Accepted
2021-05-10 08:38:47
Documents
14
Period of Report
2021-05-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT bivi-20210509_8k.htm   iXBRL 8-K 44769
2 EXHIBIT 2.2 bivi-20210509_8kex2z2.htm EX-2.2 26937
3 EXHIBIT 99.1 bivi-20210509_8kex99z1.htm EX-99.1 12748
  Complete submission text file 0001520138-21-000249.txt   272540

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bivi-20210509.xsd EX-101.SCH 3102
5 XBRL LABEL FILE bivi-20210509_lab.xml EX-101.LAB 34238
6 XBRL PRESENTATION FILE bivi-20210509_pre.xml EX-101.PRE 22371
7 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20210509_8k_htm.xml XML 3590
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

EIN.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39015 | Film No.: 21905384
SIC: 2834 Pharmaceutical Preparations